The Global Point of Care and Rapid Diagnostics Market is expected to reach USD 75.5 billion by 2027 from an estimated USD 45.4 billion in 2022, at a CAGR of 10.7% from 2022 to 2027.

The growth of the point-of-care diagnostics market can be attributed to the high prevalence of respiratory diseases such as influenza, COVID diseases, cardiac diseases, and infectious disease, (where POC tests can greatly improve the management of these diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse). Moreover, growing accessibility of POCT products through online platforms, supportive govt. Policies, and rising number of CLIA-waived POC tests. healthcare decentralization and greater investments and funding for product development are expected to accelerate the growth point of care diagnostics market in the coming years.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185

Point-of-care and rapid diagnostics industry Dynamics

Driver: Increasing prevalence of infectious diseases

Point-of-care tests with high sensitivity and specificity enable quick diagnosis of these highly infectious diseases and enable timely treatment of patients. The prevalence of infectious diseases such as HIV, Hepatitis, influenza, tuberculosis is likely to boost the demand for point-of-care diagnostics for the rapid detection of infectious diseases. Listed below are important statistics related to major infectious diseases in developing countries:

According to the National Aids Control Organization (NACO), in 2021, approximately 2.40 million people in India were infected with HIV. Of the total HIV-infected population, 45% were women, and 2% represented children below the age of 12.

According to the WHO Global TB Report 2021, of the 1.7 billion global population infected with TB, around 587 million people with TB reside in Southeast Asia (SEA).

Restraint: Pricing pressure owing to reimbursement cuts and budget constraints

The pricing pressure due to reimbursement cuts and lack of sufficient budgets has impacted the growth of the global point-of-care rapid diagnostics market. In France, all the cost of patient care is rolled out into one prospective payment under the Diagnosis Related Group (DRG) system, making reimbursement a negligible factor. In the country, the reimbursement for diabetes technologies in outpatient settings is based on a tariff system.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=106829185

Opportunity: POC tests with multiplexing capabilities

Companies are trying to develop POC devices that can run multiple analytes on a single device. These devices can simultaneously measure multiple analytes on the same cartridge, which is known as multiplexing. Multiplex POC tests offer several advantages over widely adopted singleplex tests, such as increased efficiency at lower costs, greater output per sample, and higher throughput. These advantages will help in gaining more resolute and detailed diagnostics and facilitate personalized medicine. Some examples of multiplexed devices include: The Triage 8 Panel for Drugs of Abuse from Alere is an immunoassay that determines major metabolites of drugs of abuse, providing results in 10 minutes. The commercialization of such cost-effective and advanced multiplex POC tests will offer new growth opportunities for market players.

The Asia Pacific market is expected to grow at the highest CAGR during the forecast period

The global point-of-care diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. North America is the largest market for point-of-care diagnostics market. The rising prevalence of lifestyle diseases, government initiatives to support the wider adoption of POC diagnostics, strong presence of key players in the region are anticipated to support the growth of North America point-of-care diagnostics market.

Key Market Players

Abbott Laboratories (US), Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (a Werfen Company) (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMérieux S.A. (France)

Recent Developments

• In May 2022, QuantuMDx announced the launch of its new respiratory panel test; Q-POC SARS-CoV-2, Flu A/B RSV Assay.
• In March 2022, Boditech Med entered in strategic partnership with Novo Integrated Sciences, Inc. with an aim to expand its biomarker based rapid testing product line across North America
• In January 2022, Roche launched its Cobas Pulse System in select countries accepting the CE Mark. This is Roche Diagnostics newest generation of connected point-of-care solutions for professional blood glucose management.

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=106829185

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

Email: [email protected]